Tandem Diabetes Care Stock Buy Hold or Sell Recommendation
| TNDM Stock | USD 30.81 0.07 0.23% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Tandem Diabetes Care is 'Cautious Hold'. The recommendation algorithm takes into account all of Tandem Diabetes' available fundamental, technical, and predictive indicators you will find on this site.
Check out Tandem Diabetes Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Tandem and provide practical buy, sell, or hold advice based on investors' constraints. Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Tandem |
Execute Tandem Diabetes Buy or Sell Advice
The Tandem recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Tandem Diabetes Care. Macroaxis does not own or have any residual interests in Tandem Diabetes Care or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Tandem Diabetes' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Tandem Diabetes Trading Alerts and Improvement Suggestions
| Tandem Diabetes Care generated a negative expected return over the last 90 days | |
| Tandem Diabetes Care has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 747.72 M. Net Loss for the year was (222.61 M) with profit before overhead, payroll, taxes, and interest of 412.99 M. | |
| Tandem Diabetes Care currently holds about 608.73 M in cash with (31.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.47. | |
| Tandem Diabetes Care has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 10000 shares by Blickenstaff Kim D of Tandem Diabetes at 30.0 subject to Rule 16b-3 |
Tandem Diabetes Returns Distribution Density
The distribution of Tandem Diabetes' historical returns is an attempt to chart the uncertainty of Tandem Diabetes' future price movements. The chart of the probability distribution of Tandem Diabetes daily returns describes the distribution of returns around its average expected value. We use Tandem Diabetes Care price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Tandem Diabetes returns is essential to provide solid investment advice for Tandem Diabetes.
| Mean Return | -0.44 | Value At Risk | -4.6 | Potential Upside | 4.47 | Standard Deviation | 3.16 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Tandem Diabetes historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Tandem Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Tandem Diabetes, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Tandem Diabetes Care back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Ameriprise Financial Inc | 2024-06-30 | 1.5 M | Champlain Investment Partners, Llc | 2024-09-30 | 1.5 M | Hhg Plc | 2024-06-30 | 1.5 M | Stephens Inv Mgmt Group Llc | 2024-09-30 | 1.3 M | Two Sigma Advisers, Llc | 2024-06-30 | 1.1 M | Park West Asset Management Llc | 2024-09-30 | 1.1 M | Millennium Management Llc | 2024-06-30 | 1.1 M | Divisadero Street Capital Management, Lp | 2024-09-30 | 1.1 M | First Light Asset Management, Llc | 2024-09-30 | 1 M | Blackrock Inc | 2024-06-30 | 11.1 M | Vanguard Group Inc | 2024-09-30 | 7.4 M |
Tandem Diabetes Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 9.3M | 43.4M | (23.4M) | 101.3M | (113.6M) | (108.0M) | |
| Free Cash Flow | 22.4M | (7.6M) | 87.8M | 7.5M | (83.4M) | (79.2M) | |
| Depreciation | 6.1M | 10.5M | 13.8M | 14.3M | 15.7M | 8.0M | |
| Other Non Cash Items | (321K) | 28.9M | 2.3M | 50.5M | 104.7M | 109.9M | |
| Capital Expenditures | 19.5M | 32.3M | 23.5M | 43.0M | 51.6M | 54.2M | |
| Net Income | (24.8M) | (34.4M) | 15.6M | (94.6M) | (222.6M) | (211.5M) | |
| End Period Cash Flow | 51.2M | 94.6M | 71.2M | 172.5M | 58.9M | 65.4M | |
| Change To Inventory | (31.0M) | (15.4M) | (5.0M) | (42.5M) | (46.1M) | (43.8M) | |
| Investments | (37.4M) | (263.8M) | (163.4M) | 33.2M | (85.7M) | (90.0M) | |
| Change Receivables | (13.7M) | (38.8M) | (31.0M) | (7.8M) | (7.0M) | (7.4M) | |
| Change To Netincome | 73.5M | 76.4M | 65.5M | 121.7M | 140.0M | 147.0M |
Tandem Diabetes Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Tandem Diabetes or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Tandem Diabetes' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Tandem stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.62 | |
β | Beta against Dow Jones | 1.46 | |
σ | Overall volatility | 3.11 | |
Ir | Information ratio | -0.18 |
Tandem Diabetes Volatility Alert
Tandem Diabetes Care exhibits very low volatility with skewness of 0.02 and kurtosis of 0.3. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Tandem Diabetes' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Tandem Diabetes' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Tandem Diabetes Fundamentals Vs Peers
Comparing Tandem Diabetes' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Tandem Diabetes' direct or indirect competition across all of the common fundamentals between Tandem Diabetes and the related equities. This way, we can detect undervalued stocks with similar characteristics as Tandem Diabetes or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Tandem Diabetes' fundamental indicators could also be used in its relative valuation, which is a method of valuing Tandem Diabetes by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Tandem Diabetes to competition |
| Fundamentals | Tandem Diabetes | Peer Average |
| Return On Equity | -0.46 | -0.31 |
| Return On Asset | -0.0969 | -0.14 |
| Profit Margin | (0.15) % | (1.27) % |
| Operating Margin | (0.11) % | (5.51) % |
| Current Valuation | 2.03 B | 16.62 B |
| Shares Outstanding | 65.68 M | 571.82 M |
| Shares Owned By Insiders | 0.76 % | 10.09 % |
| Shares Owned By Institutions | 99.24 % | 39.21 % |
| Number Of Shares Shorted | 8.39 M | 4.71 M |
| Price To Earning | 494.25 X | 28.72 X |
| Price To Book | 8.51 X | 9.51 X |
| Price To Sales | 2.37 X | 11.42 X |
| Revenue | 747.72 M | 9.43 B |
| Gross Profit | 412.99 M | 27.38 B |
| EBITDA | (194.66 M) | 3.9 B |
| Net Income | (222.61 M) | 570.98 M |
| Cash And Equivalents | 608.73 M | 2.7 B |
| Cash Per Share | 9.47 X | 5.01 X |
| Total Debt | 415.67 M | 5.32 B |
| Debt To Equity | 1.00 % | 48.70 % |
| Current Ratio | 4.80 X | 2.16 X |
| Book Value Per Share | 3.62 X | 1.93 K |
| Cash Flow From Operations | (31.81 M) | 971.22 M |
| Short Ratio | 6.85 X | 4.00 X |
| Earnings Per Share | (1.94) X | 3.12 X |
| Target Price | 51.3 | |
| Number Of Employees | 2.4 K | 18.84 K |
| Beta | 1.37 | -0.15 |
| Market Capitalization | 2.02 B | 19.03 B |
| Total Asset | 952.66 M | 29.47 B |
| Retained Earnings | (951.8 M) | 9.33 B |
| Working Capital | 552.73 M | 1.48 B |
| Current Asset | 106.98 M | 9.34 B |
Note: Disposition of 10000 shares by Blickenstaff Kim D of Tandem Diabetes at 30.0 subject to Rule 16b-3 [view details]
Tandem Diabetes Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Tandem . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Tandem Diabetes Buy or Sell Advice
When is the right time to buy or sell Tandem Diabetes Care? Buying financial instruments such as Tandem Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Tandem Diabetes in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Electronics Thematic Idea Now
Electronics
Companies manufacturing electronic appliances and goods. The Electronics theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronics Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Tandem Diabetes Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share 13.082 | Quarterly Revenue Growth 0.314 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.